Technology Bundle ID
TAB-2657

Development of Immune System Tolerance for the Treatment of Autoimmune Disease

Applications
Therapeutics
Linked ID
E-186-2009-0
Lead Inventors
Wanjun Chen (NIDCR)
Development Status
  • Early-stage
  • In vivo data available (animal)
Therapeutic Areas
Immunology
ICs
NIDCR
The present invention provides a therapeutic method for the treatment of autoimmune or autoinflammatory diseases by first breaking down the dysregulated immune system and then reprogramming the immune system to restore tolerance to the patient's self-antigens by induction of antigen specific regulatory T cells. The inventors have shown that only with the combination of apoptosis, phagocytes, and antigen can antigen-specific regulatory T cells (Treg) cells be optimally generated to develop long-term immune tolerance. This strategy for developing immune tolerance can be applied to the treatment of autoimmune diseases.
Commercial Applications
  • Treatment of autoimmune disease.
Competitive Advantages
CB Process - Sent email to LPM requesting details contained in Phase I of the CBP Form A and asking if new technology qualifies for the CB Process. - JLR 30APR09 CB Process - Sent RFQ to BioT Law Firm for Bid. CB Process - Firm selected. Waiting for covnerted RFQ and the additional signature to be returned.

Request More Info

Licensing Contact: